Population-based measurement of quality of diabetes care using HbA1c values in the state of Thuringia/Germany

Experimental and Clinical Endocrinology and Diabetes

Volumn 112, Issue 9, 2004, Pages 531-537

  Sämann, Alexander ^a   Kaiser, J ^a   Hunger Dathe, W ^a   Schiel, R ^a   Muller U A ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Diabetes mellitus; Epidemiology; HbA1c; Outcome quality; Public health care

Indexed keywords

HEMOGLOBIN A1C;

ARTICLE; BLOOD GLUCOSE MONITORING; DIABETES MELLITUS; GENERAL PRACTITIONER; GERMANY; HEALTH CARE QUALITY; HUMAN; LABORATORY; MAJOR CLINICAL STUDY; POPULATION RESEARCH; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; STANDARDIZATION; THURINGIA; URBAN RURAL DIFFERENCE;

BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIABETES MELLITUS; GERMANY; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; QUALITY OF HEALTH CARE;

EID: 7744227642     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-821311     Document Type: Article

References (49)

1. Abbott RD, Donahue RP, Kannel WB, Wilson PW. The impact of diabetes on survival following myocardial infarction in men vs. women. The Framingham Study. JAMA 1988; 260: 3456-3460, Erratum in: JAMA 1989; 261: 1884
2. Abbott RD, Donahue RP, Kannel WB, Wilson PW. The impact of diabetes on survival following myocardial infarction in men vs. women. The Framingham Study. JAMA 1988; 260: 3456-3460, Erratum in: JAMA 1989; 261: 1884
3. The ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2003; 288: 2981-2997
4. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabetic Medicine 1997; 14: 7-85
5. Bagust A, Hopkinson PK, Maslove L, Currie CJ. The projected health care burden of Type 2 diabetes in the UK from 2000 to 2060. Diab Med 2002; 19 (Suppl 4): 1-5
6. Berger M., Mühlhäuser I. Implementation of intensified insulin therapy. A european perspective. Diabet Med 1995; 12: 201-208
7. Berger B, Stentstrom G, Sundkvist G. Incidence, prevalence, and mortality of diabetes in a large population. A report from the Skaraborg Diabetes Registry. Diab Care 1999; 22: 773-778
8. Bertoni AG, Krop JS, Anderson GF, Brancati FL. Diabetes-related morbidity and mortality in a national sample of US elders. Diab Care 2002; 25: 471-475
9. Brun E, Nelson RG, Bennett PH, Imperatore G, Zoppini G, Verlato G, Muggeo M. Diabetes duration and cause-specific mortality in the Verona Diabetes Study. Diab Care 2000; 23: 1119-1123
10. Colman PG, Goodall GI, Garcia-Webb P, Williams PF, Dunlop ME. Glycohaemoglobin: a crucial measurement in modern diabetes management. Progress towards standardisation and improved precision of measurement. Australian Diabetes Society, the Royal College of Pathologists of Australia and the Australian Association of Clinical Biochemists [consensus development conference]. Med J Aust 1997; 167: 96-98
11. DAFNE Study Group. Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. BMJ 2002; 5: 325: 746
12. The Diabetes Control and Complication Trial Research Group (DCCT). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986
13. Dunstan DW, Zimmet PZ, Welborn TA, De Courten MP, Cameron AJ, Sicree RA, Dwyer T, Colagiuri S, Jolley D, Knuiman M, Atkins R, Shaw JE. The rising prevalence of diabetes and impaired glucose tolerance - the Australien diabetes, obesity and lifestyle study. Diab Care 2002; 25: 829-834
14. El-Agouza I, Abu Shahla A, Sirdah M. The effect of iron deficiency anaemia on the levels of haemoglobin subtypes: possible consequences for clinical diagnosis. Clin Lab Haematol 2002; 24: 285-289
15. Fluckiger R, Harmon W, Meier W, Loo S, Gabbay KH. Hemoglobin carbamylation in uremia. N Engl J Med 1981; 304: 823-827
16. Ford ES, De Stefano F. Risk factors for mortality from all causes and from coronary heart disease among persons with diabetes. Findings from the National Health and Nutrition Examination Survey I. Epidemiologic follow-up study. Am J Epi 1991; 133: 1220-1230
17. Green A, Gale EAM, Patterson CC. Incidence of childhood-onset insulin-dependent diabetes mellitus: the EURODIAB ACE study. Lancet 1992; 339: 905-909
18. Grusser M, Hoffstadt K, Jorgens V. Preventive care for early detection of diabetes mellitus complications: a model project in Wolfsburg (Article in German). ZaeFQ 2000; 94: 411-416
19. Gu K, Cowie CC, Harris M. Mortality in adults with and without diabetes in a national cohort of the U. S. population, 1971-1993. Diab Care 1998; 21: 1138-1145
20. Harris M, Hadden WC, Knowlen PH. Gennett: Prevalence of diabetes and impaired glucose tolerante and plasma glucose levels in U. S. population aged 20-74 yr. Diabetes 1987; 36: 523-534
21. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22
22. 1 fraction in alcoholism. Alcoholism Clin Experim Res 1982; 6: 260-266
23. Junghänel J, Netzer, Müller UA. Prävalenz Diabetischer Folgeerkrankungen als Qualitätsmerkmal der Diabetesbehandlung in der Hausarztpraxis in Thüringen und Mecklenburg-Vorpommern. Diab Stoffw 2001; 10(Suppl 1): 109
24. Karvonen M, Tuomilehto J, Libman I, LaPorte R. A review of the recent epidemiological data and the worldwide incidence of type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1993; 36: 883-892
25. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diab Care 1998; 22: 1414-1431
26. Liebl A, Neiss A, Spannheimer A, Reitberger U, Wieseler B, Stammer H, Goertz A. Complications, co-morbidity, and blood glucose control in type 2 diabetes mellitus patients in Germany - results from the CODE-2 study. Exp Clin Endocrinol Diabetes 2002; 110: 10-16
27. Mooy JM, Grootenhuis PA, de Vries H, Valkenburg HA, Bouter LM, Kostense PJ, Heine RJ. Prevalence and determinants of glucose intolerance in a Dutch Caucasian population. The Hoorn Study. Diabet Care 1995; 18: 1270-1273
28. Müller UA, Junghänel J, Köhler S, Köhler M, Schumann M. Quality of diabetes care in a general practice network. Exp Clin Endocrinol Diabetes 2000; 108 (Suppl 1): S 163
29. Müller UA, Femerling M, Risse A for the Working group of structured Diabetes therapy of the German Diabetes Association. HbA1c and severe hypoglycemia after intensified treatment and education of 10 000 type-1-diabetec patients. Results of a ten years nationwide quality-circle. Oral lecture on the 37th Annual Meeting of the EASD, Glasgow 9.-13.9.2001. Diabetologia 2001; 44 (Suppl 1): A16
30. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117
31. Panzram G, Zabel-Langhennig R. Prognosis of diabetes mellitus in a geographically defined population. Diabetol 1981; 20: 587-591
32. Rathmann W, Haastert B, Icks A, Löwel H, Meisinger C, Holle R, Giani G. High prevalence of undiagnosed diabetes mellitus in Southern Germany: Target populations for efficient screening. The KORA survey 2000. Diabetologia 2003; 46: 182-189
33. Reichard P, Pihl M, Rosenqvist U, Sule J. Complications in IDDM are caused by elevated blood glucose levels: The Stockholm Diabetes Intervention Study (SIDS) at 10-year follow up. Diabetologia 1996; 39: 1483-1488
34. Saemann A, Koehler S, Klinger R, Mohr Ch, Mueller UA. Mapping HbA1c values as a quality measure in the primary care of diabetes patients in Thuringia, Germany (in German). ZaeFQ 2002; 96: 615-620
35. Scandinavian Simvastatin Survival Study. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 19 (8934): 1383-1389
36. Schiel R, Muller UA, Sprott H, Schmelzer A, Merles B, Hunger-Dathe W, Ross IS. The JEVIN trial: A population-based survey on the quality of diabetes care in Germany: 1994/1995 compared to 1998/1999. Diabetologia 1997; 40: 1350-1357
37. Schulze J, Kunath H, Rothe U, Range U, Prettin C, Verlohren HJ, Fischer S. Quality of diabetes management in the free Saxony state - scientific evaluation of the Saxony model for managing diabetes. EVA group (in German). Gesundheitswesen 1996; 58 (Suppl 2): 144-148
38. SPSS ©. SPSS Inc., Chicago, Illinois, USA, 2002
39. Stede D, on behalf of The Thurigian Department of Statistics. Group IV.3 (Population). Erfurt: The Free State of Thurigia, 2002
40. Tarim O, Kucukerdogan A, Gunay U, Eralp O, Ercan I. Effects of iron deficiency anemia on hemoglobin Al c in type 1 diabetes mellitus. Pediatr Int 1999; 41: 357-362
41. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998a; 317 (7160): 713-720
42. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 b; 352: 837-853
43. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998 c; 317 (7160): 703-713; Erratum in BMJ 1999; 318 (7175): 29
44. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998 c; 317 (7160): 703-713; Erratum in BMJ 1999; 318 (7175): 29
45. Vincent Group. Diabetes care and research in Europe. The St. Vincent Declaration. Diabet Med 1989; 7: 360
46. West of Scotland Coronary Prevention Study. Identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 1996; 348 (9038): 1339-1342
47. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153; Erratum in N Engl J Med 2000; 342: 1376 and N Engl J Med 2000; 342: 748
48. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153; Erratum in N Engl J Med 2000; 342: 1376 and N Engl J Med 2000; 342: 748
49. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153; Erratum in N Engl J Med 2000; 342: 1376 and N Engl J Med 2000; 342: 748